Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crdf · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$2.00
Consensus
$2.00
+33.3% upside
Low
$2.00
Median: $2 · Last Close: $1.50
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.42 | ↓ 5.00% |
1-day model range: $1.4–$1.45. Peak: $1.45 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -46.1% |
| 2028 | $1 | -58.6% |
| 2029 | $1 | -63.3% |
| 2030 | $1 | -65.5% |
| 2031 | — | -66.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRDF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | Craig-Hallum | Downgrade ↓ | Buy→Hold |
| 2026-06-01 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-06-01 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2026-02-25 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-01-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cardiff Oncology, Inc. (CRDF) stock. Of the recent 51 rating actions, 2 were upgrades and 10 were downgrades. 14 analysts currently cover CRDF.
Analyst Recommendation Trends
CRDF analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↑ 6.1% YoY
Revenue Next Year
$0M
↓ 22.4% YoY
EPS This Year
$-0.68
EPS Next Year
$-0.82
↑ 20.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRDF EPS of $-0.68 for the current fiscal year, based on estimates from 6 analysts. The CRDF revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRDF stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRDF price target is $2.00 (+33.3% upside), with an analyst consensus of Buy.
The CRDF short-term stock prediction for tomorrow is $1.42 (-5.00%). The CRDF stock price prediction for 2027 estimates an average of $1. The CRDF stock prediction for 2030 projects a range of $0–$1.
Cardiff Oncology, Inc. trades on NASDAQ under the ticker CRDF. The CRDF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
CRDF forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month CRDF price target is $2.00, with a high forecast of $2.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +33.3% potential upside from the current price of $1.50.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.